Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced
financial results for the third quarter ended September 30, 2022.
“The third quarter was instrumental for Adverum, as we dosed our
first subject in our Phase 2 LUNA trial of Ixo-vec evaluating the
2E11 dose and a new, lower 6E10 dose, along with enhanced
prophylactic steroid regimens for the treatment of wet AMD,” stated
Laurent Fischer, M.D., president and chief executive officer of
Adverum Biotechnologies. “We look forward to sharing interim data
from LUNA throughout 2023. We are incredibly excited with our
progress in advancing our investigational gene therapy candidate
Ixo-vec, which we believe has the potential to transform the
treatment paradigm for patients with wet age-related macular
degeneration and meaningfully reduce the burden of frequent
anti-VEGF injections. The transformational potential of Ixo-vec was
recognized by the European Medicines Agency earlier this summer
with its granting Ixo-vec with Priority Medicines designation.”
Dr. Fischer continued, “We presented two-year, end of study,
safety and efficacy data from our OPTIC trial at the recent Annual
Meeting of The Retina Society, indicating that a single IVT
injection of Ixo-vec was generally well tolerated and can maintain
or improve vision, as well as improve intraretinal and subretinal
fluid volume in wet AMD patients. We are encouraged by the data
demonstrating that a single intravitreal injection of Ixo-vec can
lead to stable and persistent aflibercept protein levels through
three years resulting in better fluid control known to be
associated with favorable vision outcomes, as well as decreasing
treatment burden by an 81-98% reduction in mean annualized
anti-VEGF injections. These data strengthen the emerging
benefit-risk profile of Ixo-vec as we further evaluate the 2E11 and
6E10 doses in LUNA. We believe Ixo-vec, with its continuous
expression of aflibercept over years, can bring immense value to
patients with an improved quality of life, caregivers, retinal
specialists, payers and the healthcare systems.”
Recent Highlights
- In July 2022, Adverum completed an Investigational New Drug
amendment with the U.S. Food and Drug Administration to advance a
Phase 2 trial of Ixo-vec in wet AMD.
- In September 2022, Adverum dosed the first subject in its Phase
2 LUNA trial evaluating Ixo-vec at the 2x10^11 vg/eye (2E11) and
6x10^10 vg/eye (6E10) dose levels, with enhanced prophylactic
steroid regimens.
- Adverum presented data from the OPTIC trial of Ixo-vec at three
key scientific meetings:
- An oral presentation at the American Society of Retina
Specialists detailed an 81%-98% reduction in annualized anti-VEGF
injections and demonstrated continuous therapeutic aflibercept
protein levels through three years following a single, intravitreal
(IVT) injection of Ixo-vec. Ixo-vec was generally well tolerated at
the 2E11 dose, along with data demonstrating that mean
best-corrected visual acuity and central subfield thickness were
maintained or improved in subjects in the OPTIC trial.
- An oral presentation at the American Academy of Ophthalmology
2022 Annual Meeting detailed anatomical improvements in
intraretinal fluid (IRF) and subretinal fluid (SRF). In the 2E11
dose group, there was a 93% and 55% reduction in mean IRF and SRF
volume, respectively, from baseline to week 48, following a single
IVT dose of Ixo-vec.
- An oral presentation at The Retina Society’s 2022 Annual
Meeting detailed two-year, end of study data for all OPTIC cohorts,
including new data documenting that 80% and 53% of the participants
in the 6x10^11 vg/eye and 2E11 dose groups, respectively, were
supplemental injection free over two years.
Financial Results for the Three Months Ended September
30, 2022
- Cash, cash equivalents and short-term
investments were $203.3 million as of September 30, 2022,
compared to $305.2 million as of December 31, 2021. Adverum expects
the September 30, 2022 cash position to fund operations into
2025.
- Research and development expenses were
$23.8 million for the three months ended September 30, 2022,
compared to $24.1 million for the same period in 2021. Research and
development expenses decreased primarily due lower
facilities-related expenses, lower headcount following the
restructuring and lower consultant costs; partially offset by
restructuring costs and higher clinical trial-related expenses.
Stock-based compensation expense included in research and
development expenses was $1.4 million for the third quarter of
2022.
- General and administrative expenses were $17.2
million for the three months ended September 30, 2022, compared to
$14.5 million for the same period in 2021. General and
administrative expenses increased primarily due to reversal of
sublease income and restructuring costs; partially offset by lower
personnel-associated costs following the restructuring and
facilities-related expenses. Stock-based compensation expense
included in general and administrative expenses was $3.1 million
for the third quarter of 2022.
- Net loss was $40.1 million, or $0.40 per basic
and diluted share, for the three months ended September 30, 2022,
compared to $38.4 million, or $0.39 per basic per basic and diluted
share, for the same period in 2021.
About Wet Age-Related Macular Degeneration
Wet AMD, also known as neovascular AMD or nAMD, is an advanced
form of AMD, affecting approximately 10% of patients living with
AMD. Wet AMD is a leading cause of blindness in patients over 65
years of age, with a prevalence of approximately 20 million
individuals worldwide living with this condition. The incidence of
new cases of wet AMD is expected to grow significantly worldwide as
populations age. AMD is expected to impact 288 million people
worldwide by 2040, with wet AMD accounting for approximately 10% of
those cases.
About OPTIC Trial of ADVM-022 in Wet AMD
ADVM-022, ixoberogene soroparvovec (Ixo-vec), is Adverum’s
clinical-stage gene therapy product candidate being developed for
the treatment of wet AMD. Ixo-vec utilizes a proprietary vector
capsid, AAV.7m8, carrying an aflibercept coding sequence under the
control of a proprietary expression cassette. Unlike other
ophthalmic gene therapies that require surgery to administer the
gene therapy under the retina (sub-retinal approach) Ixo-vec has
the advantage of being administered as a one-time IVT injection in
the office and is designed to deliver long-term efficacy and reduce
the burden of frequent anti-VEGF injections, optimize patient
compliance, and improve vision outcomes for patients with wet
AMD.
The OPTIC trial is designed as a multi-center, open-label,
dose-ranging, safety, and efficacy trial of Ixo-vec in participants
with wet AMD who have demonstrated responsiveness to anti-VEGF
treatment. Patients in OPTIC are treatment-experienced, and
previously required frequent anti-VEGF injections to manage their
wet AMD and to maintain functional vision.
About LUNA Trial of Ixo-vec in Wet AMD
Ixoberogene soroparvovec (Ixo-vec) is Adverum’s clinical-stage
gene therapy product candidate being developed for the treatment of
wet AMD. Ixo-vec utilizes an engineered, proprietary vector capsid,
AAV.7m8, carrying an aflibercept coding sequence under the control
of a proprietary expression cassette. Unlike other ophthalmic gene
therapies that require surgery to administer the gene therapy under
the retina (sub-retinal approach), Ixo-vec has the advantage of
being administered as a one-time IVT injection in the office and is
designed to deliver long-term efficacy and reduce the burden of
frequent anti-vascular endothelial growth factor (VEGF) injections,
optimize patient compliance, and improve vision outcomes for
patients with wet AMD.
The LUNA trial is a multicenter, double-masked, randomized,
parallel-group Phase 2 study evaluating two doses of Ixo-vec,
including the 2x10^11 vg/eye (2E11) dose and a new, lower 6x10^10
vg/eye (6E10) dose, in wet AMD. The trial will randomize up to 72
participants equally across two doses and four prophylactic steroid
regimens in 40 sites in the U.S. and Europe. The primary endpoints
include the mean change in best-corrected visual acuity (BCVA) from
baseline to one year and the incidence and severity of adverse
events.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases with the aspiration of
developing functional cures for these diseases to restore vision
and prevent blindness. Leveraging the research capabilities of its
proprietary, intravitreal (IVT) platform, Adverum is developing
durable, single-administration therapies, designed to be delivered
in physicians’ offices, to eliminate the need for frequent ocular
injections to treat these diseases. Adverum is evaluating its novel
gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly
referred to as ADVM-022), as a one-time, IVT injection for patients
with neovascular or wet age-related macular degeneration. By
overcoming the challenges associated with current treatment
paradigms for these debilitating ocular diseases, Adverum aspires
to transform the standard of care, preserve vision, and create a
profound societal impact around the globe. For more information,
please visit www.adverum.com.
Forward-looking Statements
Statements contained in this press release regarding events or
results that may occur in the future are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include but are not limited to
statements regarding the potential benefits of Ixo-vec, the timing
of preliminary data from the LUNA trial evaluating the same, as
well as cash runway to fund operations into 2025. Actual results
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including risks inherent to, without limitation:
Adverum’s novel technology, which makes it difficult to predict the
timing of commencement and completion of clinical trials;
regulatory uncertainties; enrollment uncertainties; the results of
early clinical trials not always being predictive of future
clinical trials and results; and the potential for future
complications or side effects in connection with use of Ixo-vec.
Additional risks and uncertainties facing Adverum are set forth
under the caption “Risk Factors” and elsewhere in Adverum’s
Securities and Exchange Commission (SEC) filings and reports,
including Adverum’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2022 filed with the SEC on August 11, 2022. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Adverum undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Corporate & Investor Inquiries
Anand ReddiVice President, Head of Corporate Strategy, External
Affairs and EngagementAdverum Biotechnologies, Inc.T:
650-649-1358E: areddi@adverum.com
Media
Megan TalonAssociate Director, Corporate CommunicationsAdverum
Biotechnologies, Inc.T: 650-649-1006E: mtalon@adverum.com
Adverum Biotechnologies, Inc. |
Consolidated Balance Sheets |
(In thousands) |
|
|
|
|
|
|
|
September 30 |
|
December 31 |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
(Unaudited) |
|
|
(1) |
|
Assets |
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash equivalents |
|
$ |
84,430 |
|
|
$ |
34,195 |
|
Short-term investments |
|
|
118,834 |
|
|
|
270,993 |
|
Lease incentive receivable |
|
|
- |
|
|
|
5,709 |
|
Prepaid expenses and other current assets |
|
9,979 |
|
|
|
6,248 |
|
Total current assets |
|
|
213,243 |
|
|
|
317,145 |
|
Property and equipment, net |
|
|
36,579 |
|
|
|
33,060 |
|
Operating lease right-of-use assets |
|
|
79,882 |
|
|
|
86,000 |
|
Restricted cash |
|
|
2,503 |
|
|
|
2,503 |
|
Deferred rent receivable |
|
|
- |
|
|
|
769 |
|
Deposit and other long-term assets |
|
|
155 |
|
|
|
250 |
|
Total assets |
|
$ |
332,362 |
|
|
$ |
439,727 |
|
|
|
|
|
|
Liabilities and stockholders' equity |
|
|
|
|
Current liabilities: |
|
|
|
|
Accounts payable |
|
$ |
846 |
|
|
$ |
1,387 |
|
Lease liability, current portion |
|
|
11,236 |
|
|
|
1,886 |
|
Accrued expenses and other current liabilities |
|
|
16,539 |
|
|
|
18,047 |
|
Total current liabilities |
|
|
28,621 |
|
|
|
21,320 |
|
Lease liability, net of current portion |
|
|
94,464 |
|
|
|
101,108 |
|
Other noncurrent liabilities |
|
|
940 |
|
|
|
1,114 |
|
Total liabilities |
|
|
124,025 |
|
|
|
123,542 |
|
Stockholders' equity: |
|
|
|
|
Common stock |
|
|
10 |
|
|
|
10 |
|
Additional paid-in capital |
|
|
980,156 |
|
|
|
964,965 |
|
Accumulated other comprehensive loss |
|
|
(1,953 |
) |
|
|
(714 |
) |
Accumulated deficit |
|
|
(769,876 |
) |
|
|
(648,076 |
) |
Total stockholders' equity |
|
|
208,337 |
|
|
|
316,185 |
|
Total liabilities and stockholders' equity |
$ |
332,362 |
|
|
$ |
439,727 |
|
|
|
|
|
|
(1) Derived from Adverum's annual audited consolidated financial
statements. |
|
|
|
|
|
Adverum Biotechnologies, Inc. |
Consolidated Statements of Operations |
(In thousands except per share data) |
|
|
|
|
|
|
|
|
|
|
|
Three months endedSeptember 30, |
|
Nine months endedSeptember 30, |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
License revenue |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
7,500 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development |
|
|
23,849 |
|
|
|
24,069 |
|
|
|
77,078 |
|
|
|
66,657 |
|
General and administrative |
|
|
17,188 |
|
|
|
14,453 |
|
|
|
46,117 |
|
|
|
52,546 |
|
Total operating expenses |
|
|
41,037 |
|
|
|
38,522 |
|
|
|
123,195 |
|
|
|
119,203 |
|
Operating loss |
|
|
(41,037 |
) |
|
|
(38,522 |
) |
|
|
(123,195 |
) |
|
|
(111,703 |
) |
Other income, net |
|
|
923 |
|
|
|
160 |
|
|
|
1,450 |
|
|
|
572 |
|
Net loss before income taxes |
|
|
(40,114 |
) |
|
|
(38,362 |
) |
|
|
(121,745 |
) |
|
|
(111,131 |
) |
Income tax provision |
|
|
(17 |
) |
|
|
- |
|
|
|
(55 |
) |
|
|
- |
|
Net loss |
|
$ |
(40,131 |
) |
|
$ |
(38,362 |
) |
|
$ |
(121,800 |
) |
|
$ |
(111,131 |
) |
Net loss per share — basic and diluted |
|
$ |
(0.40 |
) |
|
$ |
(0.39 |
) |
|
$ |
(1.23 |
) |
|
$ |
(1.13 |
) |
Weighted-average common shares outstanding - basic and diluted |
|
|
99,475 |
|
|
|
98,126 |
|
|
|
99,027 |
|
|
|
97,966 |
|
|
|
|
|
|
|
|
|
|
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024